 J. Steven Leeder
Concepts (846)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytochrome P-450 CYP2D6 | 50 | 2023 | 180 | 9.220 |
Why?
| | Pharmacogenetics | 45 | 2023 | 170 | 8.700 |
Why?
| | Cytochrome P-450 Enzyme System | 44 | 2023 | 88 | 6.400 |
Why?
| | Liver | 37 | 2023 | 119 | 6.030 |
Why?
| | Humans | 243 | 2024 | 6599 | 5.920 |
Why?
| | Pharmacokinetics | 10 | 2021 | 14 | 3.820 |
Why?
| | Genotype | 63 | 2024 | 395 | 3.700 |
Why?
| | Child | 86 | 2024 | 3146 | 3.650 |
Why?
| | Microsomes, Liver | 22 | 2023 | 42 | 3.590 |
Why?
| | Cytochrome P-450 CYP3A | 26 | 2020 | 46 | 3.510 |
Why?
| | Pharmaceutical Preparations | 15 | 2021 | 36 | 3.070 |
Why?
| | Female | 94 | 2021 | 3436 | 3.040 |
Why?
| | Adolescent | 64 | 2022 | 2087 | 2.930 |
Why?
| | Genetic Variation | 21 | 2024 | 161 | 2.840 |
Why?
| | Male | 91 | 2021 | 3197 | 2.810 |
Why?
| | Precision Medicine | 9 | 2019 | 42 | 2.780 |
Why?
| | Methotrexate | 12 | 2018 | 27 | 2.550 |
Why?
| | Hypercholesterolemia | 3 | 2024 | 12 | 2.360 |
Why?
| | Child, Preschool | 49 | 2022 | 1459 | 2.350 |
Why?
| | Adult | 48 | 2024 | 1233 | 2.270 |
Why?
| | Aging | 9 | 2021 | 32 | 2.190 |
Why?
| | Infant, Newborn | 45 | 2022 | 790 | 2.140 |
Why?
| | Dextromethorphan | 24 | 2022 | 55 | 2.090 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2020 | 22 | 2.080 |
Why?
| | Child Development | 10 | 2022 | 42 | 2.030 |
Why?
| | Models, Biological | 11 | 2023 | 46 | 2.020 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 17 | 2023 | 41 | 2.000 |
Why?
| | Dose-Response Relationship, Drug | 18 | 2020 | 92 | 2.000 |
Why?
| | Infant | 44 | 2022 | 1396 | 1.980 |
Why?
| | Polymorphism, Single Nucleotide | 23 | 2021 | 340 | 1.970 |
Why?
| | Biotransformation | 26 | 2021 | 49 | 1.950 |
Why?
| | Atomoxetine Hydrochloride | 4 | 2021 | 9 | 1.870 |
Why?
| | Gene Expression Regulation, Developmental | 10 | 2020 | 33 | 1.850 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 3 | 2019 | 17 | 1.800 |
Why?
| | Age Factors | 23 | 2020 | 203 | 1.790 |
Why?
| | Phenotype | 33 | 2022 | 233 | 1.700 |
Why?
| | Arthritis, Juvenile | 8 | 2016 | 30 | 1.650 |
Why?
| | Cerebral Palsy | 3 | 2023 | 16 | 1.630 |
Why?
| | Fetus | 7 | 2018 | 16 | 1.610 |
Why?
| | Alleles | 22 | 2021 | 197 | 1.520 |
Why?
| | Alternative Splicing | 5 | 2020 | 17 | 1.450 |
Why?
| | Anticonvulsants | 9 | 2018 | 25 | 1.420 |
Why?
| | Young Adult | 20 | 2021 | 652 | 1.400 |
Why?
| | Polymorphism, Genetic | 14 | 2019 | 89 | 1.390 |
Why?
| | Proteins | 5 | 2023 | 22 | 1.370 |
Why?
| | Polymerase Chain Reaction | 11 | 2015 | 82 | 1.360 |
Why?
| | Inactivation, Metabolic | 8 | 2018 | 15 | 1.360 |
Why?
| | Pediatrics | 7 | 2012 | 170 | 1.290 |
Why?
| | Analgesics, Opioid | 9 | 2021 | 44 | 1.290 |
Why?
| | Drug Dosage Calculations | 5 | 2021 | 16 | 1.280 |
Why?
| | Adrenergic Uptake Inhibitors | 2 | 2019 | 5 | 1.260 |
Why?
| | Carbamazepine | 8 | 2011 | 10 | 1.240 |
Why?
| | Biomarkers | 9 | 2023 | 120 | 1.240 |
Why?
| | Chromatography, High Pressure Liquid | 16 | 2019 | 41 | 1.210 |
Why?
| | Lung | 12 | 2017 | 65 | 1.160 |
Why?
| | Epigenesis, Genetic | 3 | 2016 | 64 | 1.130 |
Why?
| | Glucuronosyltransferase | 8 | 2020 | 16 | 1.110 |
Why?
| | Gene Frequency | 14 | 2016 | 88 | 1.090 |
Why?
| | Animals | 31 | 2021 | 563 | 1.090 |
Why?
| | Anti-Infective Agents | 3 | 2016 | 21 | 1.060 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 5 | 2020 | 11 | 1.040 |
Why?
| | Genetic Testing | 7 | 2019 | 74 | 1.020 |
Why?
| | Drug Interactions | 9 | 2022 | 30 | 1.020 |
Why?
| | Pravastatin | 3 | 2020 | 7 | 1.020 |
Why?
| | Pregnancy | 14 | 2019 | 203 | 1.010 |
Why?
| | Pteroylpolyglutamic Acids | 3 | 2014 | 3 | 1.000 |
Why?
| | Folic Acid | 4 | 2019 | 16 | 1.000 |
Why?
| | RNA, Messenger | 13 | 2018 | 107 | 0.980 |
Why?
| | Middle Aged | 20 | 2021 | 648 | 0.980 |
Why?
| | Polyglutamic Acid | 4 | 2011 | 4 | 0.970 |
Why?
| | Promoter Regions, Genetic | 5 | 2016 | 47 | 0.970 |
Why?
| | Genomics | 5 | 2022 | 86 | 0.960 |
Why?
| | Acetaminophen | 8 | 2019 | 17 | 0.940 |
Why?
| | Dystonic Disorders | 1 | 2023 | 4 | 0.940 |
Why?
| | Dystonia | 1 | 2023 | 7 | 0.930 |
Why?
| | Tandem Mass Spectrometry | 7 | 2019 | 19 | 0.920 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2014 | 13 | 0.920 |
Why?
| | Membrane Transport Proteins | 7 | 2022 | 12 | 0.910 |
Why?
| | Folic Acid Antagonists | 2 | 2013 | 2 | 0.900 |
Why?
| | Receptors, Steroid | 3 | 2016 | 4 | 0.890 |
Why?
| | Indomethacin | 2 | 2022 | 4 | 0.890 |
Why?
| | Antipsychotic Agents | 3 | 2020 | 14 | 0.880 |
Why?
| | Drug Design | 3 | 2010 | 7 | 0.850 |
Why?
| | Drug Hypersensitivity | 7 | 1998 | 19 | 0.840 |
Why?
| | Narcotic Antagonists | 1 | 2021 | 3 | 0.830 |
Why?
| | Naltrexone | 1 | 2021 | 4 | 0.830 |
Why?
| | Simvastatin | 2 | 2019 | 10 | 0.820 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 44 | 0.810 |
Why?
| | Haplotypes | 7 | 2023 | 81 | 0.790 |
Why?
| | Gene Expression Regulation, Enzymologic | 8 | 2016 | 19 | 0.780 |
Why?
| | Metabolic Clearance Rate | 8 | 2023 | 18 | 0.770 |
Why?
| | Pimozide | 1 | 2020 | 4 | 0.770 |
Why?
| | Erythrocytes | 4 | 2014 | 11 | 0.770 |
Why?
| | Trimethoprim | 3 | 2016 | 11 | 0.760 |
Why?
| | Drug Delivery Systems | 2 | 2019 | 5 | 0.750 |
Why?
| | Rosuvastatin Calcium | 1 | 2020 | 5 | 0.750 |
Why?
| | Baclofen | 2 | 2017 | 9 | 0.740 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 5 | 2018 | 8 | 0.740 |
Why?
| | Maternal Exposure | 3 | 2017 | 3 | 0.730 |
Why?
| | Umbilical Cord | 1 | 2019 | 1 | 0.730 |
Why?
| | Cytokines | 5 | 2018 | 48 | 0.720 |
Why?
| | Cytosol | 6 | 2023 | 13 | 0.700 |
Why?
| | Codeine | 6 | 2014 | 15 | 0.690 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 40 | 0.690 |
Why?
| | Abnormalities, Drug-Induced | 3 | 2008 | 9 | 0.690 |
Why?
| | Opioid-Related Disorders | 3 | 2015 | 15 | 0.690 |
Why?
| | Biological Transport | 6 | 2022 | 16 | 0.660 |
Why?
| | Tissue Distribution | 4 | 2015 | 10 | 0.660 |
Why?
| | Breast Feeding | 7 | 2011 | 23 | 0.650 |
Why?
| | Research Design | 4 | 2019 | 64 | 0.640 |
Why?
| | DNA Methylation | 2 | 2016 | 108 | 0.640 |
Why?
| | Placenta | 4 | 2017 | 19 | 0.640 |
Why?
| | DNA Copy Number Variations | 3 | 2020 | 31 | 0.630 |
Why?
| | Common Cold | 2 | 2015 | 2 | 0.630 |
Why?
| | Nonprescription Drugs | 2 | 2015 | 2 | 0.630 |
Why?
| | Cough | 2 | 2015 | 7 | 0.630 |
Why?
| | Central Nervous System Stimulants | 4 | 2016 | 10 | 0.630 |
Why?
| | Antitussive Agents | 8 | 2015 | 13 | 0.630 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2015 | 7 | 0.620 |
Why?
| | Brain | 3 | 2007 | 74 | 0.620 |
Why?
| | Cytochrome P-450 CYP2C19 | 10 | 2023 | 54 | 0.620 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 3 | 2007 | 4 | 0.610 |
Why?
| | Aged | 10 | 2021 | 375 | 0.610 |
Why?
| | Asthma | 7 | 2015 | 143 | 0.600 |
Why?
| | Genetics, Population | 2 | 2016 | 11 | 0.590 |
Why?
| | Gene Duplication | 3 | 2010 | 10 | 0.590 |
Why?
| | Proteomics | 6 | 2022 | 19 | 0.590 |
Why?
| | Gestational Age | 12 | 2017 | 61 | 0.580 |
Why?
| | Knowledge Bases | 1 | 2016 | 6 | 0.580 |
Why?
| | Smoking | 2 | 2017 | 69 | 0.580 |
Why?
| | Sequence Analysis, DNA | 7 | 2022 | 106 | 0.570 |
Why?
| | Gene Expression Profiling | 9 | 2016 | 109 | 0.570 |
Why?
| | Intestine, Small | 1 | 2016 | 14 | 0.560 |
Why?
| | Cytosine | 1 | 2016 | 4 | 0.560 |
Why?
| | Tetrahydrofolates | 2 | 2014 | 3 | 0.560 |
Why?
| | Crohn Disease | 1 | 2016 | 21 | 0.560 |
Why?
| | Oxygenases | 3 | 2017 | 5 | 0.550 |
Why?
| | Minor Histocompatibility Antigens | 4 | 2020 | 11 | 0.550 |
Why?
| | DNA | 6 | 2013 | 39 | 0.550 |
Why?
| | Opiate Substitution Treatment | 1 | 2015 | 1 | 0.540 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 2015 | 2 | 0.540 |
Why?
| | Molecular Sequence Data | 11 | 2015 | 65 | 0.540 |
Why?
| | Mice | 17 | 2018 | 290 | 0.530 |
Why?
| | Valproic Acid | 2 | 2013 | 2 | 0.520 |
Why?
| | Absorption | 3 | 2014 | 7 | 0.520 |
Why?
| | Health Care Costs | 2 | 2019 | 29 | 0.520 |
Why?
| | Cotinine | 2 | 2017 | 5 | 0.490 |
Why?
| | Statistics as Topic | 3 | 2016 | 18 | 0.480 |
Why?
| | Arylsulfotransferase | 2 | 2011 | 8 | 0.480 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2013 | 1 | 0.470 |
Why?
| | Erythroblasts | 1 | 2013 | 1 | 0.470 |
Why?
| | Ribonucleotides | 1 | 2013 | 1 | 0.470 |
Why?
| | Anti-Allergic Agents | 1 | 2013 | 6 | 0.470 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2013 | 10 | 0.460 |
Why?
| | Histamine | 1 | 2013 | 11 | 0.460 |
Why?
| | Caffeine | 7 | 2006 | 12 | 0.460 |
Why?
| | Steroid 16-alpha-Hydroxylase | 3 | 2001 | 6 | 0.450 |
Why?
| | Maternal Behavior | 1 | 2012 | 2 | 0.450 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2010 | 39 | 0.450 |
Why?
| | Phenytoin | 5 | 2012 | 8 | 0.450 |
Why?
| | Treatment Outcome | 6 | 2023 | 624 | 0.450 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 7 | 0.440 |
Why?
| | Cisapride | 2 | 2003 | 2 | 0.440 |
Why?
| | Genetic Predisposition to Disease | 7 | 2017 | 215 | 0.440 |
Why?
| | Morphine | 4 | 2018 | 11 | 0.440 |
Why?
| | Metabolic Networks and Pathways | 4 | 2013 | 10 | 0.440 |
Why?
| | Dyslipidemias | 1 | 2012 | 14 | 0.440 |
Why?
| | Antirheumatic Agents | 4 | 2014 | 14 | 0.440 |
Why?
| | Hydroxylation | 5 | 2016 | 12 | 0.430 |
Why?
| | Area Under Curve | 8 | 2019 | 34 | 0.430 |
Why?
| | Gene Expression | 7 | 2015 | 60 | 0.420 |
Why?
| | Base Sequence | 8 | 2015 | 76 | 0.410 |
Why?
| | Body Weight | 3 | 2022 | 49 | 0.410 |
Why?
| | Carboxylic Acids | 1 | 2011 | 1 | 0.410 |
Why?
| | Metabolome | 1 | 2011 | 3 | 0.410 |
Why?
| | Models, Genetic | 3 | 2007 | 33 | 0.410 |
Why?
| | Infant, Premature | 4 | 2022 | 81 | 0.400 |
Why?
| | Receptors, Opioid, mu | 2 | 2021 | 4 | 0.400 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 64 | 0.400 |
Why?
| | Mass Spectrometry | 6 | 2011 | 16 | 0.400 |
Why?
| | Isoenzymes | 5 | 2017 | 19 | 0.390 |
Why?
| | Risk Assessment | 5 | 2015 | 130 | 0.390 |
Why?
| | Hospitalization | 1 | 2012 | 192 | 0.390 |
Why?
| | United States | 8 | 2018 | 646 | 0.390 |
Why?
| | Case-Control Studies | 7 | 2017 | 202 | 0.390 |
Why?
| | Longitudinal Studies | 3 | 2022 | 123 | 0.380 |
Why?
| | Obesity | 2 | 2022 | 124 | 0.380 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2010 | 2 | 0.380 |
Why?
| | Gene Dosage | 1 | 2010 | 8 | 0.380 |
Why?
| | Risk Factors | 6 | 2015 | 460 | 0.370 |
Why?
| | Drug Evaluation | 1 | 2010 | 1 | 0.370 |
Why?
| | Mixed Function Oxygenases | 5 | 2003 | 14 | 0.370 |
Why?
| | Sulfates | 2 | 2019 | 6 | 0.370 |
Why?
| | Tandem Repeat Sequences | 1 | 2010 | 4 | 0.370 |
Why?
| | Intensive Care Units, Neonatal | 3 | 2018 | 31 | 0.370 |
Why?
| | Cluster Analysis | 4 | 2011 | 43 | 0.360 |
Why?
| | Administration, Oral | 6 | 2017 | 59 | 0.360 |
Why?
| | Drug Costs | 1 | 2009 | 4 | 0.350 |
Why?
| | Cohort Studies | 7 | 2017 | 264 | 0.350 |
Why?
| | Cell Survival | 5 | 1993 | 19 | 0.350 |
Why?
| | Infant, Newborn, Diseases | 1 | 2009 | 32 | 0.350 |
Why?
| | Enzymes | 2 | 2021 | 4 | 0.340 |
Why?
| | Exons | 6 | 2013 | 32 | 0.340 |
Why?
| | Carbon Dioxide | 1 | 2008 | 16 | 0.340 |
Why?
| | Breath Tests | 1 | 2008 | 11 | 0.340 |
Why?
| | Transcriptome | 3 | 2018 | 50 | 0.330 |
Why?
| | Oxidoreductases, N-Demethylating | 5 | 2003 | 8 | 0.330 |
Why?
| | Antibodies | 3 | 1997 | 15 | 0.330 |
Why?
| | Enzyme Inhibitors | 6 | 2016 | 19 | 0.320 |
Why?
| | Steroid Hydroxylases | 4 | 2007 | 9 | 0.320 |
Why?
| | Sulfamethoxazole | 5 | 1991 | 5 | 0.320 |
Why?
| | Predictive Value of Tests | 6 | 2017 | 99 | 0.320 |
Why?
| | Prospective Studies | 8 | 2022 | 508 | 0.320 |
Why?
| | Anti-Ulcer Agents | 3 | 2010 | 8 | 0.320 |
Why?
| | Metronidazole | 2 | 2019 | 14 | 0.320 |
Why?
| | Metabolomics | 2 | 2020 | 13 | 0.320 |
Why?
| | Testosterone | 4 | 2020 | 11 | 0.310 |
Why?
| | Binding Sites | 5 | 2015 | 26 | 0.310 |
Why?
| | DNA Primers | 5 | 2015 | 27 | 0.310 |
Why?
| | Organic Cation Transporter 1 | 2 | 2018 | 4 | 0.310 |
Why?
| | Nicotine | 2 | 2019 | 11 | 0.300 |
Why?
| | Depressive Disorder, Major | 2 | 2023 | 14 | 0.300 |
Why?
| | Analgesics, Non-Narcotic | 3 | 2018 | 7 | 0.300 |
Why?
| | Dextrorphan | 5 | 2022 | 13 | 0.290 |
Why?
| | Protein Isoforms | 3 | 2020 | 16 | 0.290 |
Why?
| | Sulfonamides | 2 | 1997 | 10 | 0.290 |
Why?
| | Midazolam | 6 | 2015 | 11 | 0.280 |
Why?
| | Substrate Specificity | 5 | 2016 | 16 | 0.280 |
Why?
| | Computational Biology | 3 | 2013 | 40 | 0.280 |
Why?
| | Anti-Infective Agents, Urinary | 2 | 2016 | 4 | 0.280 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 98 | 0.280 |
Why?
| | Muscle Relaxants, Central | 2 | 2017 | 7 | 0.280 |
Why?
| | Gene Rearrangement | 1 | 2006 | 8 | 0.280 |
Why?
| | Cross-Sectional Studies | 3 | 2019 | 317 | 0.280 |
Why?
| | Dibenzazepines | 1 | 2005 | 2 | 0.270 |
Why?
| | Endoplasmic Reticulum | 2 | 1997 | 3 | 0.270 |
Why?
| | RNA Splicing | 3 | 2015 | 11 | 0.270 |
Why?
| | Glutathione | 6 | 2005 | 11 | 0.270 |
Why?
| | Algorithms | 3 | 2010 | 103 | 0.270 |
Why?
| | Recombinant Proteins | 4 | 2020 | 47 | 0.260 |
Why?
| | Sulfotransferases | 2 | 2019 | 7 | 0.260 |
Why?
| | Kinetics | 11 | 2008 | 30 | 0.260 |
Why?
| | Tacrolimus | 2 | 2015 | 10 | 0.260 |
Why?
| | Arylamine N-Acetyltransferase | 5 | 2005 | 18 | 0.260 |
Why?
| | Genetic Association Studies | 4 | 2014 | 53 | 0.250 |
Why?
| | Methylation | 5 | 2016 | 11 | 0.250 |
Why?
| | Fetal Diseases | 1 | 2004 | 5 | 0.250 |
Why?
| | Sensitivity and Specificity | 5 | 2016 | 145 | 0.250 |
Why?
| | Immunosuppressive Agents | 2 | 2015 | 37 | 0.250 |
Why?
| | Congenital Abnormalities | 1 | 2004 | 11 | 0.250 |
Why?
| | Indians, North American | 2 | 2001 | 9 | 0.250 |
Why?
| | Rats | 9 | 2011 | 97 | 0.250 |
Why?
| | Acetylcysteine | 5 | 2016 | 9 | 0.250 |
Why?
| | Specimen Handling | 1 | 2004 | 18 | 0.250 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 76 | 0.250 |
Why?
| | Heterozygote | 1 | 2024 | 23 | 0.240 |
Why?
| | Retrospective Studies | 5 | 2021 | 1251 | 0.240 |
Why?
| | Antidepressive Agents | 2 | 2023 | 19 | 0.240 |
Why?
| | Cytochrome P-450 CYP1A2 | 6 | 2006 | 12 | 0.240 |
Why?
| | In Vitro Techniques | 7 | 2016 | 20 | 0.240 |
Why?
| | Phenols | 2 | 2016 | 6 | 0.230 |
Why?
| | Milk, Human | 4 | 2011 | 21 | 0.230 |
Why?
| | RNA Interference | 1 | 2003 | 15 | 0.230 |
Why?
| | Xanthine Oxidase | 6 | 2005 | 14 | 0.230 |
Why?
| | Trichophyton | 2 | 2015 | 5 | 0.230 |
Why?
| | Databases, Genetic | 3 | 2017 | 25 | 0.230 |
Why?
| | Cytochrome P-450 CYP2B6 | 3 | 2023 | 10 | 0.230 |
Why?
| | Anesthesia | 1 | 2002 | 3 | 0.230 |
Why?
| | Naphthalenes | 2 | 1999 | 6 | 0.220 |
Why?
| | Chromatography, Liquid | 4 | 2019 | 8 | 0.220 |
Why?
| | Organic Anion Transporters | 2 | 2020 | 8 | 0.220 |
Why?
| | Body Height | 1 | 2022 | 31 | 0.210 |
Why?
| | Oximes | 1 | 2021 | 1 | 0.210 |
Why?
| | Mitochondrial Proteins | 1 | 2021 | 7 | 0.210 |
Why?
| | Pain | 2 | 2021 | 53 | 0.210 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 1 | 2021 | 2 | 0.210 |
Why?
| | Hyperlipidemias | 2 | 2019 | 6 | 0.210 |
Why?
| | Transcription, Genetic | 3 | 2013 | 44 | 0.210 |
Why?
| | Body Surface Area | 1 | 2021 | 11 | 0.200 |
Why?
| | Rare Diseases | 1 | 2022 | 37 | 0.200 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 94 | 0.200 |
Why?
| | Maternal-Fetal Exchange | 3 | 2015 | 6 | 0.200 |
Why?
| | Catechol O-Methyltransferase | 1 | 2021 | 5 | 0.200 |
Why?
| | Terminology as Topic | 2 | 2017 | 14 | 0.200 |
Why?
| | Body Mass Index | 1 | 2022 | 155 | 0.200 |
Why?
| | Prescription Drugs | 1 | 2021 | 4 | 0.200 |
Why?
| | Warfarin | 4 | 2014 | 12 | 0.200 |
Why?
| | Overweight | 1 | 2021 | 48 | 0.200 |
Why?
| | Morpholines | 2 | 2018 | 2 | 0.200 |
Why?
| | Autoantigens | 2 | 1998 | 5 | 0.190 |
Why?
| | Adverse Drug Reaction Reporting Systems | 3 | 2010 | 13 | 0.190 |
Why?
| | Sex Characteristics | 3 | 2017 | 13 | 0.190 |
Why?
| | Tourette Syndrome | 1 | 2020 | 6 | 0.190 |
Why?
| | Principal Component Analysis | 4 | 2016 | 13 | 0.190 |
Why?
| | United States Food and Drug Administration | 2 | 2010 | 6 | 0.190 |
Why?
| | Kidney | 2 | 2019 | 89 | 0.190 |
Why?
| | Pilot Projects | 2 | 2019 | 124 | 0.190 |
Why?
| | Aborted Fetus | 1 | 2020 | 1 | 0.190 |
Why?
| | Androstadienes | 2 | 2013 | 2 | 0.190 |
Why?
| | Stillbirth | 1 | 2020 | 2 | 0.190 |
Why?
| | Netherlands | 1 | 2020 | 4 | 0.190 |
Why?
| | Epitopes | 2 | 1998 | 19 | 0.180 |
Why?
| | Dietary Supplements | 1 | 2019 | 18 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 57 | 0.180 |
Why?
| | Drug Overdose | 4 | 2015 | 4 | 0.180 |
Why?
| | Aquaporin 1 | 1 | 2019 | 1 | 0.180 |
Why?
| | Aquaporin 2 | 1 | 2019 | 1 | 0.180 |
Why?
| | Prognosis | 2 | 2017 | 209 | 0.180 |
Why?
| | Organic Anion Transporters, Sodium-Independent | 2 | 2016 | 3 | 0.180 |
Why?
| | Multidrug Resistance-Associated Proteins | 2 | 2016 | 5 | 0.180 |
Why?
| | Antifungal Agents | 2 | 2015 | 13 | 0.180 |
Why?
| | Reproducibility of Results | 6 | 2016 | 197 | 0.180 |
Why?
| | Linear Models | 4 | 2017 | 55 | 0.180 |
Why?
| | Infant Formula | 2 | 2011 | 15 | 0.180 |
Why?
| | Time Factors | 7 | 2014 | 241 | 0.180 |
Why?
| | Omeprazole | 4 | 2010 | 12 | 0.170 |
Why?
| | Sequence Alignment | 2 | 2015 | 9 | 0.170 |
Why?
| | Cytochrome P-450 CYP2A6 | 1 | 2019 | 3 | 0.170 |
Why?
| | Benzodiazepines | 2 | 2018 | 3 | 0.170 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 11 | 0.170 |
Why?
| | Analgesics | 2 | 2015 | 5 | 0.170 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 38 | 0.170 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 238 | 0.170 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 1998 | 5 | 0.170 |
Why?
| | Urine Specimen Collection | 1 | 2018 | 1 | 0.170 |
Why?
| | Proton Pump Inhibitors | 1 | 2018 | 13 | 0.170 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2018 | 4 | 0.170 |
Why?
| | Glucuronides | 1 | 2018 | 3 | 0.170 |
Why?
| | Protective Agents | 1 | 2018 | 2 | 0.160 |
Why?
| | Androgens | 1 | 2018 | 2 | 0.160 |
Why?
| | Research | 2 | 2018 | 11 | 0.160 |
Why?
| | Fluorescent Dyes | 3 | 1993 | 5 | 0.160 |
Why?
| | Renin-Angiotensin System | 1 | 2018 | 5 | 0.160 |
Why?
| | Intracellular Space | 1 | 2018 | 1 | 0.160 |
Why?
| | Adenosine Triphosphate | 1 | 2018 | 3 | 0.160 |
Why?
| | Anticoagulants | 2 | 2014 | 17 | 0.160 |
Why?
| | Infant, Premature, Diseases | 1 | 2018 | 23 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 34 | 0.160 |
Why?
| | Gastroesophageal Reflux | 1 | 2018 | 41 | 0.160 |
Why?
| | Antiemetics | 2 | 2017 | 4 | 0.160 |
Why?
| | Enzyme Induction | 3 | 2012 | 4 | 0.160 |
Why?
| | Telomere Shortening | 1 | 2017 | 1 | 0.160 |
Why?
| | Intestinal Mucosa | 2 | 2017 | 34 | 0.160 |
Why?
| | Patient Safety | 2 | 2015 | 20 | 0.160 |
Why?
| | Contraceptive Agents | 1 | 2018 | 15 | 0.160 |
Why?
| | Sulfonylurea Receptors | 1 | 2017 | 3 | 0.160 |
Why?
| | Hypersensitivity, Delayed | 1 | 1997 | 2 | 0.160 |
Why?
| | Proto-Oncogene Proteins | 2 | 2014 | 17 | 0.160 |
Why?
| | Lung Diseases | 2 | 2016 | 23 | 0.160 |
Why?
| | Heat-Shock Proteins | 1 | 1997 | 6 | 0.160 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 13 | 0.160 |
Why?
| | Reference Values | 4 | 2014 | 40 | 0.160 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 1 | 0.160 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 129 | 0.160 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2017 | 3 | 0.160 |
Why?
| | Alcohol Dehydrogenase | 1 | 2017 | 4 | 0.160 |
Why?
| | Hypersensitivity | 1 | 1998 | 51 | 0.150 |
Why?
| | Genetic Heterogeneity | 1 | 2007 | 5 | 0.150 |
Why?
| | Vomiting | 2 | 2017 | 23 | 0.150 |
Why?
| | Neonatal Screening | 1 | 2017 | 7 | 0.150 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2016 | 2 | 0.150 |
Why?
| | Carboxylesterase | 1 | 2016 | 2 | 0.150 |
Why?
| | Oseltamivir | 1 | 2016 | 6 | 0.150 |
Why?
| | Oxidation-Reduction | 3 | 2015 | 9 | 0.150 |
Why?
| | Public Health | 1 | 2017 | 20 | 0.150 |
Why?
| | Mutagenesis, Site-Directed | 3 | 2020 | 19 | 0.150 |
Why?
| | Genome, Human | 2 | 2010 | 82 | 0.150 |
Why?
| | Adolescent Development | 1 | 2016 | 4 | 0.150 |
Why?
| | Computer Simulation | 1 | 2016 | 22 | 0.140 |
Why?
| | Propylamines | 1 | 2016 | 3 | 0.140 |
Why?
| | Down-Regulation | 1 | 2016 | 14 | 0.140 |
Why?
| | Microfilament Proteins | 1 | 2016 | 12 | 0.140 |
Why?
| | Fluoresceins | 2 | 1993 | 2 | 0.140 |
Why?
| | Lactones | 1 | 2016 | 3 | 0.140 |
Why?
| | Bupropion | 1 | 2015 | 11 | 0.140 |
Why?
| | Pediatric Obesity | 1 | 2018 | 127 | 0.140 |
Why?
| | Antigens | 1 | 1995 | 3 | 0.140 |
Why?
| | Regression Analysis | 3 | 2011 | 56 | 0.140 |
Why?
| | Nasal Decongestants | 1 | 2015 | 1 | 0.140 |
Why?
| | Antipyretics | 1 | 2015 | 1 | 0.140 |
Why?
| | Histamine Antagonists | 1 | 2015 | 8 | 0.130 |
Why?
| | Immunohistochemistry | 3 | 2015 | 36 | 0.130 |
Why?
| | Vitamin K | 2 | 2005 | 5 | 0.130 |
Why?
| | Beclomethasone | 1 | 2015 | 2 | 0.130 |
Why?
| | Retinoid X Receptors | 2 | 2005 | 3 | 0.130 |
Why?
| | RNA | 2 | 2005 | 14 | 0.130 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 7 | 0.130 |
Why?
| | Canada | 4 | 2009 | 31 | 0.130 |
Why?
| | Anti-Asthmatic Agents | 1 | 2015 | 11 | 0.130 |
Why?
| | Dexamethasone | 1 | 2015 | 30 | 0.130 |
Why?
| | Fluoxetine | 1 | 2014 | 6 | 0.130 |
Why?
| | Cross-Over Studies | 4 | 2019 | 32 | 0.130 |
Why?
| | Genes, Reporter | 2 | 2005 | 11 | 0.130 |
Why?
| | Bone Neoplasms | 1 | 2015 | 23 | 0.130 |
Why?
| | Introns | 2 | 2005 | 7 | 0.130 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 61 | 0.130 |
Why?
| | Esterases | 2 | 1991 | 2 | 0.130 |
Why?
| | Cystic Fibrosis | 2 | 2004 | 18 | 0.120 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2014 | 2 | 0.120 |
Why?
| | Acute-Phase Proteins | 1 | 2014 | 1 | 0.120 |
Why?
| | Lipocalins | 1 | 2014 | 1 | 0.120 |
Why?
| | Cephalosporins | 2 | 1984 | 15 | 0.120 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 11 | 0.120 |
Why?
| | Genetic Loci | 2 | 2013 | 37 | 0.120 |
Why?
| | Cell Line | 3 | 2013 | 80 | 0.120 |
Why?
| | Ethanolamines | 2 | 2005 | 4 | 0.120 |
Why?
| | Vitamin D | 1 | 2013 | 21 | 0.120 |
Why?
| | Tramadol | 2 | 2005 | 4 | 0.120 |
Why?
| | K562 Cells | 1 | 2013 | 3 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 28 | 0.120 |
Why?
| | Iontophoresis | 1 | 2013 | 4 | 0.120 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2013 | 5 | 0.120 |
Why?
| | Epigenomics | 1 | 2013 | 26 | 0.120 |
Why?
| | Methionine Sulfoximine | 1 | 1993 | 1 | 0.120 |
Why?
| | Rhinitis, Allergic | 1 | 2013 | 10 | 0.120 |
Why?
| | Genotyping Techniques | 1 | 2013 | 21 | 0.120 |
Why?
| | Kidney Transplantation | 1 | 2014 | 114 | 0.120 |
Why?
| | Autoantibodies | 1 | 1993 | 9 | 0.110 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2012 | 1 | 0.110 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2012 | 2 | 0.110 |
Why?
| | Models, Animal | 1 | 2012 | 6 | 0.110 |
Why?
| | Bronchodilator Agents | 1 | 2013 | 11 | 0.110 |
Why?
| | ROC Curve | 1 | 2012 | 18 | 0.110 |
Why?
| | Up-Regulation | 1 | 2012 | 25 | 0.110 |
Why?
| | Diarrhea | 1 | 2012 | 18 | 0.110 |
Why?
| | Soft Tissue Infections | 1 | 2012 | 11 | 0.110 |
Why?
| | Inhibitory Concentration 50 | 2 | 2020 | 7 | 0.110 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1992 | 3 | 0.110 |
Why?
| | Stereoisomerism | 3 | 2020 | 9 | 0.110 |
Why?
| | Body Size | 1 | 2012 | 7 | 0.110 |
Why?
| | Genome-Wide Association Study | 4 | 2017 | 181 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 1992 | 33 | 0.110 |
Why?
| | Cells, Cultured | 5 | 2011 | 73 | 0.110 |
Why?
| | Deferoxamine | 2 | 1989 | 3 | 0.110 |
Why?
| | Ferredoxin-NADP Reductase | 1 | 2012 | 1 | 0.110 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2012 | 6 | 0.110 |
Why?
| | Cloning, Molecular | 2 | 2005 | 7 | 0.110 |
Why?
| | Cytochrome P-450 CYP2C9 | 4 | 2014 | 25 | 0.110 |
Why?
| | Antimanic Agents | 1 | 2011 | 1 | 0.110 |
Why?
| | Gene Deletion | 1 | 2011 | 12 | 0.110 |
Why?
| | Saliva | 1 | 2011 | 10 | 0.110 |
Why?
| | RNA 3' End Processing | 1 | 2011 | 1 | 0.100 |
Why?
| | Blood | 1 | 2011 | 10 | 0.100 |
Why?
| | Hepatocytes | 1 | 2011 | 6 | 0.100 |
Why?
| | Isoflavones | 1 | 2011 | 1 | 0.100 |
Why?
| | Soybean Proteins | 1 | 2011 | 1 | 0.100 |
Why?
| | Soy Foods | 1 | 2011 | 2 | 0.100 |
Why?
| | Citalopram | 2 | 2023 | 13 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2011 | 23 | 0.100 |
Why?
| | Lactic Acid | 1 | 2011 | 3 | 0.100 |
Why?
| | Clozapine | 2 | 2003 | 3 | 0.100 |
Why?
| | Transcription Factors | 2 | 2015 | 46 | 0.100 |
Why?
| | Antioxidants | 1 | 2011 | 5 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2018 | 150 | 0.100 |
Why?
| | Killer Cells, Natural | 1 | 1991 | 12 | 0.100 |
Why?
| | Sex Factors | 3 | 2020 | 71 | 0.100 |
Why?
| | Government Regulation | 1 | 2010 | 1 | 0.100 |
Why?
| | Betaine-Homocysteine S-Methyltransferase | 1 | 2010 | 2 | 0.100 |
Why?
| | Toll-Like Receptors | 1 | 2010 | 12 | 0.100 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2010 | 1 | 0.100 |
Why?
| | Drug Administration Routes | 1 | 2010 | 3 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 45 | 0.090 |
Why?
| | China | 2 | 2001 | 8 | 0.090 |
Why?
| | Forecasting | 2 | 2022 | 20 | 0.090 |
Why?
| | Disulfides | 1 | 2010 | 2 | 0.090 |
Why?
| | 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2010 | 6 | 0.090 |
Why?
| | Expectorants | 1 | 2010 | 2 | 0.090 |
Why?
| | Models, Statistical | 2 | 2014 | 34 | 0.090 |
Why?
| | Patient Selection | 1 | 2010 | 40 | 0.090 |
Why?
| | Hybridization, Genetic | 1 | 2010 | 3 | 0.090 |
Why?
| | Tinea | 1 | 2010 | 4 | 0.090 |
Why?
| | Environmental Pollutants | 1 | 2009 | 1 | 0.090 |
Why?
| | Benzhydryl Compounds | 1 | 2009 | 3 | 0.090 |
Why?
| | Fetal Development | 1 | 2009 | 4 | 0.090 |
Why?
| | Wnt Proteins | 1 | 2009 | 11 | 0.090 |
Why?
| | HEK293 Cells | 2 | 2020 | 30 | 0.090 |
Why?
| | National Health Programs | 1 | 2009 | 1 | 0.090 |
Why?
| | Gastroschisis | 1 | 2009 | 21 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2010 | 142 | 0.090 |
Why?
| | Economics, Pharmaceutical | 1 | 2009 | 1 | 0.090 |
Why?
| | Child Health Services | 1 | 2009 | 24 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1989 | 9 | 0.090 |
Why?
| | Iron | 1 | 1989 | 13 | 0.090 |
Why?
| | Drugs, Investigational | 1 | 2008 | 1 | 0.090 |
Why?
| | Investigational New Drug Application | 1 | 2008 | 1 | 0.090 |
Why?
| | Schizophrenia | 1 | 2008 | 3 | 0.080 |
Why?
| | Carbon Isotopes | 1 | 2008 | 4 | 0.080 |
Why?
| | Protein Binding | 2 | 2007 | 30 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 44 | 0.080 |
Why?
| | Lymphocytes | 1 | 1988 | 15 | 0.080 |
Why?
| | Feasibility Studies | 1 | 2008 | 66 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2008 | 69 | 0.080 |
Why?
| | Pyridines | 2 | 1988 | 4 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2004 | 4 | 0.080 |
Why?
| | Hospitals, Pediatric | 1 | 2009 | 178 | 0.080 |
Why?
| | Nausea | 2 | 2018 | 15 | 0.080 |
Why?
| | Pedigree | 2 | 2022 | 53 | 0.080 |
Why?
| | Transfection | 2 | 2004 | 19 | 0.080 |
Why?
| | Amino Acid Sequence | 2 | 1998 | 27 | 0.080 |
Why?
| | Healthy Volunteers | 2 | 2019 | 8 | 0.080 |
Why?
| | Dealkylation | 1 | 2007 | 2 | 0.080 |
Why?
| | Buserelin | 1 | 1986 | 1 | 0.070 |
Why?
| | Puberty, Precocious | 1 | 1986 | 1 | 0.070 |
Why?
| | Mice, SCID | 3 | 1996 | 12 | 0.070 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2020 | 20 | 0.070 |
Why?
| | Paroxetine | 1 | 2006 | 3 | 0.070 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2006 | 4 | 0.070 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2006 | 6 | 0.070 |
Why?
| | Genetic Markers | 3 | 2015 | 20 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 3 | 2006 | 5 | 0.070 |
Why?
| | Open Reading Frames | 1 | 2006 | 3 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 1 | 2006 | 11 | 0.070 |
Why?
| | Antimetabolites | 2 | 2018 | 4 | 0.070 |
Why?
| | Theophylline | 1 | 1986 | 2 | 0.070 |
Why?
| | Contraceptives, Oral | 1 | 2005 | 2 | 0.070 |
Why?
| | Ethinyl Estradiol | 1 | 2005 | 2 | 0.070 |
Why?
| | Norgestrel | 1 | 2005 | 2 | 0.070 |
Why?
| | Dogs | 3 | 2018 | 16 | 0.070 |
Why?
| | Xenobiotics | 1 | 2005 | 3 | 0.070 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2005 | 3 | 0.070 |
Why?
| | Heart Defects, Congenital | 1 | 2007 | 81 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2018 | 315 | 0.070 |
Why?
| | COS Cells | 2 | 2002 | 17 | 0.070 |
Why?
| | Haptens | 2 | 1996 | 3 | 0.070 |
Why?
| | Cross Reactions | 2 | 1997 | 7 | 0.070 |
Why?
| | HLA Antigens | 2 | 2011 | 12 | 0.070 |
Why?
| | Half-Life | 4 | 2014 | 10 | 0.070 |
Why?
| | Dehydroepiandrosterone | 1 | 2005 | 2 | 0.070 |
Why?
| | Catalysis | 1 | 2005 | 4 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 1997 | 46 | 0.070 |
Why?
| | Doxylamine | 2 | 1988 | 2 | 0.070 |
Why?
| | Pyridoxine | 2 | 1988 | 2 | 0.070 |
Why?
| | Luciferases | 1 | 2005 | 6 | 0.070 |
Why?
| | Metoprolol | 1 | 2004 | 3 | 0.070 |
Why?
| | Drug Combinations | 5 | 2005 | 18 | 0.070 |
Why?
| | Models, Molecular | 2 | 2007 | 14 | 0.060 |
Why?
| | Cytochrome P-450 CYP2E1 | 2 | 1996 | 4 | 0.060 |
Why?
| | Dimerization | 1 | 2004 | 3 | 0.060 |
Why?
| | Plasmids | 1 | 2004 | 4 | 0.060 |
Why?
| | Drug Eruptions | 1 | 2004 | 3 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2018 | 12 | 0.060 |
Why?
| | Hypertension | 1 | 2004 | 59 | 0.060 |
Why?
| | Administration, Inhalation | 2 | 2015 | 19 | 0.060 |
Why?
| | Legislation, Drug | 1 | 1983 | 2 | 0.060 |
Why?
| | Myocardium | 1 | 2003 | 8 | 0.060 |
Why?
| | Information Theory | 1 | 2003 | 1 | 0.060 |
Why?
| | Drug Therapy | 1 | 2003 | 7 | 0.060 |
Why?
| | Signal Transduction | 2 | 2017 | 107 | 0.060 |
Why?
| | Serotonin | 1 | 2023 | 4 | 0.060 |
Why?
| | Animals, Newborn | 2 | 2015 | 23 | 0.060 |
Why?
| | Technology, Pharmaceutical | 1 | 2003 | 1 | 0.060 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2023 | 7 | 0.060 |
Why?
| | Databases, Protein | 1 | 2003 | 2 | 0.060 |
Why?
| | LLC-PK1 Cells | 1 | 2003 | 1 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2003 | 9 | 0.060 |
Why?
| | Swine | 1 | 2003 | 5 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2003 | 10 | 0.060 |
Why?
| | Acetyltransferases | 2 | 2003 | 4 | 0.060 |
Why?
| | Mutation, Missense | 1 | 2003 | 24 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 26 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2002 | 8 | 0.060 |
Why?
| | Epoxide Hydrolases | 2 | 2005 | 6 | 0.060 |
Why?
| | Herpesvirus 4, Human | 2 | 1993 | 5 | 0.060 |
Why?
| | Lymphoma | 2 | 1993 | 9 | 0.060 |
Why?
| | Anti-Anxiety Agents | 2 | 2000 | 5 | 0.050 |
Why?
| | Debrisoquin | 1 | 2002 | 5 | 0.050 |
Why?
| | Imines | 2 | 1993 | 3 | 0.050 |
Why?
| | Benzoquinones | 2 | 1993 | 3 | 0.050 |
Why?
| | Genome | 1 | 2022 | 30 | 0.050 |
Why?
| | Human Genome Project | 1 | 2002 | 3 | 0.050 |
Why?
| | Oxidoreductases | 1 | 2021 | 9 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2002 | 5 | 0.050 |
Why?
| | Genetics, Medical | 1 | 2002 | 5 | 0.050 |
Why?
| | Menstrual Cycle | 2 | 1998 | 6 | 0.050 |
Why?
| | Hepatobiliary Elimination | 1 | 2021 | 2 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2021 | 7 | 0.050 |
Why?
| | Organ Size | 1 | 2021 | 13 | 0.050 |
Why?
| | Methyltransferases | 1 | 2001 | 9 | 0.050 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2001 | 10 | 0.050 |
Why?
| | Fluorescence | 2 | 1991 | 5 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 116 | 0.050 |
Why?
| | Ceftazidime | 3 | 1985 | 4 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 114 | 0.050 |
Why?
| | Iatrogenic Disease | 1 | 2000 | 7 | 0.050 |
Why?
| | Fluticasone | 2 | 2013 | 2 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1999 | 8 | 0.050 |
Why?
| | Phenobarbital | 2 | 1993 | 2 | 0.050 |
Why?
| | Marketing of Health Services | 1 | 2019 | 3 | 0.050 |
Why?
| | Drug Labeling | 1 | 2019 | 4 | 0.050 |
Why?
| | Sertraline | 1 | 2019 | 10 | 0.050 |
Why?
| | Immunoblotting | 2 | 1998 | 11 | 0.050 |
Why?
| | Kidney Tubules, Proximal | 1 | 2019 | 1 | 0.040 |
Why?
| | Kidney Tubules, Collecting | 1 | 2019 | 3 | 0.040 |
Why?
| | Glucuronates | 1 | 1999 | 2 | 0.040 |
Why?
| | Hospital Costs | 1 | 2019 | 27 | 0.040 |
Why?
| | Inappropriate Prescribing | 1 | 2019 | 27 | 0.040 |
Why?
| | Fluvoxamine | 1 | 1998 | 2 | 0.040 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2018 | 1 | 0.040 |
Why?
| | Zidovudine | 1 | 2018 | 3 | 0.040 |
Why?
| | Pirenzepine | 1 | 1998 | 1 | 0.040 |
Why?
| | Thromboxane-A Synthase | 1 | 1998 | 2 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 1998 | 2 | 0.040 |
Why?
| | Epitope Mapping | 1 | 1998 | 7 | 0.040 |
Why?
| | Neutrophils | 1 | 1998 | 11 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2018 | 13 | 0.040 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2018 | 3 | 0.040 |
Why?
| | Factor V | 1 | 2018 | 3 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2018 | 54 | 0.040 |
Why?
| | Homeostasis | 1 | 2018 | 7 | 0.040 |
Why?
| | Models, Immunological | 1 | 1998 | 1 | 0.040 |
Why?
| | Gene Silencing | 1 | 2018 | 13 | 0.040 |
Why?
| | Necrosis | 1 | 2017 | 2 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2018 | 55 | 0.040 |
Why?
| | Epilepsy | 1 | 1998 | 14 | 0.040 |
Why?
| | Isomerases | 1 | 1997 | 1 | 0.040 |
Why?
| | Precipitin Tests | 1 | 1997 | 1 | 0.040 |
Why?
| | Protein Disulfide-Isomerases | 1 | 1997 | 1 | 0.040 |
Why?
| | Molecular Chaperones | 1 | 1997 | 6 | 0.040 |
Why?
| | Quetiapine Fumarate | 1 | 2017 | 1 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C9 Inducers | 1 | 2017 | 1 | 0.040 |
Why?
| | Oxycodone | 1 | 2017 | 4 | 0.040 |
Why?
| | Ethanol | 1 | 2017 | 7 | 0.040 |
Why?
| | Incidence | 1 | 2017 | 125 | 0.040 |
Why?
| | Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2017 | 4 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 38 | 0.040 |
Why?
| | Carrier Proteins | 1 | 1997 | 32 | 0.040 |
Why?
| | Citric Acid Cycle | 1 | 2017 | 1 | 0.040 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2017 | 1 | 0.040 |
Why?
| | NAD | 1 | 2017 | 2 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 9 | 0.040 |
Why?
| | Embryonic Stem Cells | 1 | 2017 | 7 | 0.040 |
Why?
| | Gene Amplification | 1 | 2007 | 4 | 0.040 |
Why?
| | Databases, Factual | 1 | 2017 | 105 | 0.040 |
Why?
| | Triglycerides | 1 | 2017 | 20 | 0.040 |
Why?
| | Genomic Structural Variation | 1 | 2017 | 3 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 1996 | 24 | 0.040 |
Why?
| | Genetic Research | 1 | 2017 | 6 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 36 | 0.040 |
Why?
| | Exome | 1 | 2017 | 34 | 0.040 |
Why?
| | Intestines | 1 | 2017 | 26 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 29 | 0.040 |
Why?
| | Demography | 1 | 2016 | 10 | 0.040 |
Why?
| | Tyrphostins | 1 | 1996 | 1 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1996 | 5 | 0.040 |
Why?
| | Nitriles | 1 | 1996 | 3 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1996 | 5 | 0.040 |
Why?
| | Binding Sites, Antibody | 1 | 1996 | 4 | 0.040 |
Why?
| | Consensus Sequence | 1 | 1996 | 3 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 9 | 0.040 |
Why?
| | Gene Library | 1 | 1996 | 5 | 0.040 |
Why?
| | Isomerism | 1 | 2016 | 2 | 0.040 |
Why?
| | Blotting, Western | 1 | 1996 | 16 | 0.040 |
Why?
| | Peptide Fragments | 1 | 1996 | 12 | 0.040 |
Why?
| | Consumer Product Safety | 1 | 1995 | 1 | 0.030 |
Why?
| | Prilocaine | 1 | 1995 | 1 | 0.030 |
Why?
| | Lidocaine | 1 | 1995 | 6 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 1995 | 1 | 0.030 |
Why?
| | Antibody Specificity | 1 | 1995 | 8 | 0.030 |
Why?
| | High-Throughput Screening Assays | 1 | 2015 | 4 | 0.030 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2015 | 1 | 0.030 |
Why?
| | Organ Transplantation | 1 | 2015 | 5 | 0.030 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2015 | 4 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2015 | 32 | 0.030 |
Why?
| | Diarrhea, Infantile | 1 | 1995 | 2 | 0.030 |
Why?
| | Biomedical Research | 1 | 2015 | 20 | 0.030 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 60 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 15 | 0.030 |
Why?
| | Disease Management | 1 | 2015 | 36 | 0.030 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2014 | 1 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 84 | 0.030 |
Why?
| | Neoplasms | 1 | 2017 | 119 | 0.030 |
Why?
| | Disease Progression | 1 | 2015 | 104 | 0.030 |
Why?
| | CpG Islands | 1 | 2014 | 51 | 0.030 |
Why?
| | Counseling | 1 | 1995 | 60 | 0.030 |
Why?
| | Clotrimazole | 1 | 2014 | 3 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2015 | 50 | 0.030 |
Why?
| | Gene Ontology | 1 | 2014 | 6 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2014 | 7 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 1991 | 11 | 0.030 |
Why?
| | International Normalized Ratio | 1 | 2014 | 4 | 0.030 |
Why?
| | Receptors, Virus | 1 | 2014 | 2 | 0.030 |
Why?
| | Risk | 1 | 2014 | 40 | 0.030 |
Why?
| | Immunocompetence | 1 | 1993 | 1 | 0.030 |
Why?
| | Tumor Virus Infections | 1 | 1993 | 1 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2014 | 74 | 0.030 |
Why?
| | Hemorrhage | 1 | 2014 | 18 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 1993 | 31 | 0.030 |
Why?
| | Hep G2 Cells | 1 | 2013 | 6 | 0.030 |
Why?
| | Cardiac Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 34 | 0.030 |
Why?
| | Glutathione Reductase | 2 | 1991 | 2 | 0.030 |
Why?
| | Transition Temperature | 1 | 2013 | 2 | 0.030 |
Why?
| | Joints | 1 | 2013 | 3 | 0.030 |
Why?
| | Buthionine Sulfoximine | 1 | 1993 | 2 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1993 | 4 | 0.030 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 1993 | 1 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 38 | 0.030 |
Why?
| | Epilepsies, Partial | 1 | 1993 | 5 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 23 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2014 | 177 | 0.030 |
Why?
| | Deuterium | 1 | 2011 | 1 | 0.030 |
Why?
| | Isotope Labeling | 1 | 2011 | 1 | 0.030 |
Why?
| | Phenethylamines | 1 | 2011 | 4 | 0.030 |
Why?
| | Ions | 1 | 2011 | 2 | 0.030 |
Why?
| | Polyadenylation | 1 | 2011 | 2 | 0.030 |
Why?
| | Phytoestrogens | 1 | 2011 | 2 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2011 | 41 | 0.030 |
Why?
| | Odds Ratio | 1 | 2011 | 53 | 0.030 |
Why?
| | Methylamines | 1 | 2011 | 1 | 0.030 |
Why?
| | Metabolism, Inborn Errors | 1 | 2011 | 6 | 0.030 |
Why?
| | Digoxin | 1 | 1991 | 1 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1991 | 1 | 0.030 |
Why?
| | Cell Membrane | 1 | 1991 | 7 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 290 | 0.020 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2002 | 5 | 0.020 |
Why?
| | Morphogenesis | 1 | 2010 | 7 | 0.020 |
Why?
| | Toll-Like Receptor 2 | 1 | 2010 | 4 | 0.020 |
Why?
| | Calcium | 1 | 1990 | 36 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2010 | 11 | 0.020 |
Why?
| | Systems Biology | 1 | 2010 | 4 | 0.020 |
Why?
| | DNA, Ribosomal Spacer | 1 | 2010 | 2 | 0.020 |
Why?
| | Emigration and Immigration | 1 | 2010 | 2 | 0.020 |
Why?
| | Geography | 1 | 2010 | 2 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2010 | 3 | 0.020 |
Why?
| | Asia | 1 | 2010 | 9 | 0.020 |
Why?
| | Australia | 1 | 2010 | 9 | 0.020 |
Why?
| | DNA, Fungal | 1 | 2010 | 4 | 0.020 |
Why?
| | Virulence | 1 | 2010 | 7 | 0.020 |
Why?
| | Dithionitrobenzoic Acid | 1 | 1989 | 1 | 0.020 |
Why?
| | Microchemistry | 1 | 1989 | 1 | 0.020 |
Why?
| | Nitrobenzoates | 1 | 1989 | 1 | 0.020 |
Why?
| | Vital Capacity | 1 | 2009 | 6 | 0.020 |
Why?
| | Europe | 1 | 2010 | 33 | 0.020 |
Why?
| | North America | 1 | 2010 | 42 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 10 | 0.020 |
Why?
| | Pulmonary Surfactants | 1 | 2009 | 2 | 0.020 |
Why?
| | Hypnotics and Sedatives | 2 | 2000 | 5 | 0.020 |
Why?
| | Delayed-Action Preparations | 2 | 1987 | 4 | 0.020 |
Why?
| | Hearing Loss | 1 | 2009 | 4 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 8 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2009 | 8 | 0.020 |
Why?
| | Anthracyclines | 1 | 2009 | 7 | 0.020 |
Why?
| | Program Development | 1 | 2009 | 16 | 0.020 |
Why?
| | Heart Diseases | 1 | 2009 | 17 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 1989 | 1 | 0.020 |
Why?
| | Monocytes | 1 | 1989 | 9 | 0.020 |
Why?
| | Mutation | 1 | 2010 | 194 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 1988 | 2 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 1988 | 13 | 0.020 |
Why?
| | Apnea | 1 | 2008 | 5 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2008 | 48 | 0.020 |
Why?
| | Tetrazolium Salts | 1 | 1988 | 1 | 0.020 |
Why?
| | Thiazoles | 1 | 1988 | 1 | 0.020 |
Why?
| | NADP | 1 | 1988 | 2 | 0.020 |
Why?
| | Glutathione Transferase | 1 | 1988 | 2 | 0.020 |
Why?
| | Dicyclomine | 2 | 1988 | 2 | 0.020 |
Why?
| | Structure-Activity Relationship | 2 | 1999 | 6 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 96 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2007 | 4 | 0.020 |
Why?
| | Erythromycin | 1 | 2007 | 3 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2007 | 2 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2007 | 4 | 0.020 |
Why?
| | Software | 1 | 2007 | 24 | 0.020 |
Why?
| | Quinidine | 1 | 1987 | 1 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 6 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 1986 | 3 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 1986 | 8 | 0.020 |
Why?
| | Antibody Formation | 1 | 1986 | 4 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 1986 | 7 | 0.020 |
Why?
| | Ketoconazole | 1 | 2006 | 1 | 0.020 |
Why?
| | Mifepristone | 1 | 2006 | 2 | 0.020 |
Why?
| | Fruit | 1 | 1986 | 11 | 0.020 |
Why?
| | Psychometrics | 1 | 2006 | 33 | 0.020 |
Why?
| | Therapeutic Equivalency | 1 | 2005 | 4 | 0.020 |
Why?
| | Tobramycin | 1 | 1985 | 3 | 0.020 |
Why?
| | Dosage Forms | 1 | 2005 | 1 | 0.020 |
Why?
| | Transferases | 1 | 2005 | 1 | 0.020 |
Why?
| | Gentamicins | 1 | 1985 | 5 | 0.020 |
Why?
| | Infant, Low Birth Weight | 1 | 1985 | 13 | 0.020 |
Why?
| | Sputum | 1 | 1984 | 2 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1984 | 13 | 0.020 |
Why?
| | Pseudomonas aeruginosa | 1 | 1984 | 7 | 0.020 |
Why?
| | Blood Pressure | 1 | 2004 | 56 | 0.020 |
Why?
| | Pseudomonas Infections | 1 | 1984 | 7 | 0.020 |
Why?
| | Glucagon | 1 | 1984 | 3 | 0.020 |
Why?
| | Public Opinion | 1 | 1983 | 2 | 0.020 |
Why?
| | Drug Industry | 1 | 1983 | 2 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2003 | 4 | 0.020 |
Why?
| | Molecular Structure | 1 | 2003 | 4 | 0.020 |
Why?
| | Vitamins | 1 | 2003 | 10 | 0.020 |
Why?
| | Microsomes | 1 | 2003 | 5 | 0.020 |
Why?
| | Computer Graphics | 1 | 2003 | 1 | 0.010 |
Why?
| | Computer Systems | 1 | 2003 | 1 | 0.010 |
Why?
| | Programming Languages | 1 | 2003 | 1 | 0.010 |
Why?
| | RNA Splice Sites | 1 | 2003 | 1 | 0.010 |
Why?
| | E-Box Elements | 1 | 2003 | 1 | 0.010 |
Why?
| | Response Elements | 1 | 2003 | 2 | 0.010 |
Why?
| | User-Computer Interface | 1 | 2003 | 10 | 0.010 |
Why?
| | Transplantation, Heterologous | 2 | 1993 | 6 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 2002 | 2 | 0.010 |
Why?
| | Birth Weight | 2 | 1995 | 27 | 0.010 |
Why?
| | Protein Conformation | 1 | 1999 | 4 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 1999 | 5 | 0.010 |
Why?
| | Volunteers | 1 | 1999 | 2 | 0.010 |
Why?
| | Follicular Phase | 1 | 1998 | 3 | 0.010 |
Why?
| | Luteal Phase | 1 | 1998 | 3 | 0.010 |
Why?
| | Cytochrome P-450 CYP1A2 Inhibitors | 1 | 1998 | 1 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1998 | 24 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1998 | 7 | 0.010 |
Why?
| | Hypochlorous Acid | 1 | 1998 | 1 | 0.010 |
Why?
| | Immune Sera | 1 | 1998 | 1 | 0.010 |
Why?
| | Peroxidase | 1 | 1998 | 1 | 0.010 |
Why?
| | Rats, Inbred Lew | 1 | 1998 | 1 | 0.010 |
Why?
| | Rabbits | 1 | 1998 | 5 | 0.010 |
Why?
| | Bone Marrow | 1 | 1998 | 6 | 0.010 |
Why?
| | Free Radical Scavengers | 1 | 1998 | 1 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 5 | 0.010 |
Why?
| | Cell Division | 1 | 1996 | 5 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1996 | 5 | 0.010 |
Why?
| | Janus Kinase 2 | 1 | 1996 | 8 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 1996 | 23 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1995 | 34 | 0.010 |
Why?
| | Patient Compliance | 1 | 1995 | 70 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1993 | 5 | 0.010 |
Why?
| | Cell-Free System | 1 | 1991 | 1 | 0.010 |
Why?
| | Lymphocyte Transfusion | 1 | 1991 | 1 | 0.010 |
Why?
| | Mice, Nude | 1 | 1991 | 10 | 0.010 |
Why?
| | DNA, Viral | 1 | 1991 | 13 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1991 | 55 | 0.010 |
Why?
| | Glucose | 1 | 1991 | 22 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1991 | 18 | 0.010 |
Why?
| | Aniline Compounds | 1 | 1990 | 1 | 0.010 |
Why?
| | Mitogens | 1 | 1990 | 2 | 0.010 |
Why?
| | Ionophores | 1 | 1990 | 3 | 0.010 |
Why?
| | Xanthenes | 1 | 1990 | 2 | 0.010 |
Why?
| | Indoles | 1 | 1990 | 3 | 0.010 |
Why?
| | Ciprofloxacin | 1 | 1989 | 3 | 0.010 |
Why?
| | Thalassemia | 1 | 1989 | 2 | 0.010 |
Why?
| | Teratogens | 1 | 1988 | 5 | 0.010 |
Why?
| | Biological Availability | 1 | 1987 | 7 | 0.000 |
Why?
| | Mathematics | 1 | 1985 | 1 | 0.000 |
Why?
| | Meningitis | 1 | 1985 | 3 | 0.000 |
Why?
| | Hydrocephalus | 1 | 1985 | 8 | 0.000 |
Why?
| | Infusions, Parenteral | 1 | 1985 | 5 | 0.000 |
Why?
| | Myocardial Contraction | 1 | 1984 | 7 | 0.000 |
Why?
| | Heart Rate | 1 | 1984 | 26 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|